IARJSET ISSN (O) 2393-8021, ISSN (P) 2394-1588

International Advanced Research Journal in Science, Engineering and Technology

Impact Factor 8.311 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 13, Issue 11, November 2026

Predicting Pharmaceutical Supply Chain Disruptions Through AI-Enabled Risk Intelligence

Prof. Gaikwad R.B[1], Omkar Bapusaheb Mandlik[2]

Adsul Technical Campus, Ahilyanagar, Maharashtra, India[1,2]

Abstract: Pharmaceutical supply chains operate within an increasingly interconnected and uncertain environment, where disruptions can affect medicine availability, healthcare delivery, operational continuity, and public health outcomes. Conventional supply chain risk management approaches frequently depend on historical reporting, periodic supplier assessments, and reactive inventory decisions. Although these practices remain important, they may be insufficient for identifying emerging vulnerabilities in complex pharmaceutical distribution networks. This study examines the potential of artificial intelligence (AI)-enabled risk intelligence to predict pharmaceutical supply chain disruptions and support proactive decision-making. Drawing upon supply chain resilience theory, dynamic capabilities theory, information processing theory, and predictive analytics literature, the paper develops a conceptual framework that integrates machine learning, predictive modelling, real-time data monitoring, and intelligent risk assessment. The framework considers multiple disruption indicators, including supplier concentration, manufacturing interruptions, transportation instability, geopolitical uncertainty, regulatory changes, demand fluctuations, and inventory vulnerabilities. It proposes that integrating internal operational information with external risk signals can improve disruption forecasting, strengthen supply chain visibility, and support timely mitigation strategies. The study also identifies critical implementation challenges, particularly fragmented data systems, algorithmic opacity, cybersecurity exposure, model reliability, and unequal technological capabilities among pharmaceutical supply chain participants. The proposed framework positions AI not merely as an automation instrument but as a strategic risk intelligence capability connecting early-warning mechanisms with managerial intervention. The paper contributes to pharmaceutical supply chain research by developing an integrated predictive perspective that connects technological capabilities with organizational resilience and medicine availability. It further outlines implications for pharmaceutical manufacturers, distributors, healthcare institutions, regulators, and policymakers seeking to establish more transparent, responsive, and resilient medicine supply networks.

Keywords: Artificial Intelligence; Pharmaceutical Supply Chain; Predictive Analytics; Supply Chain Resilience; Risk Intelligence; Machine Learning; Healthcare Logistics.

I. INTRODUCTION

The pharmaceutical industry occupies a distinctive position within the global economy because its supply chain performance directly influences public health, patient safety, and the continuity of healthcare services. Unlike many conventional commercial products, medicines are essential goods whose availability cannot always be substituted without clinical consequences. A delay in delivering a consumer product may create inconvenience, whereas a shortage of an essential medicine can interrupt treatment, increase healthcare expenditure, and potentially threaten patient lives.

Pharmaceutical supply chains are particularly complex because they involve several interconnected activities, including raw material procurement, active pharmaceutical ingredient (API) manufacturing, formulation development, quality testing, regulatory approval, packaging, warehousing, transportation, and distribution to hospitals, pharmacies, and other healthcare providers. These activities are frequently distributed across multiple geographical locations and organizational boundaries. Consequently, a disruption occurring at one stage can affect the performance of the entire network.

The COVID-19 pandemic demonstrated the vulnerability of globally interconnected pharmaceutical supply chains. Manufacturing shutdowns, transportation restrictions, export limitations, workforce shortages, and unexpected increases in medicine demand exposed weaknesses in existing procurement and distribution systems. The pandemic also highlighted the strategic importance of pharmaceutical manufacturing capabilities, supplier diversification, inventory visibility, and coordinated government intervention.

© IARJSET This work is licensed under a Creative Commons Attribution 4.0 International License

Nevertheless, supply chain disruptions are not restricted to extraordinary public health emergencies. Pharmaceutical organizations regularly encounter risks arising from geopolitical instability, natural disasters, supplier failures, quality-related production interruptions, regulatory changes, cybersecurity incidents, transportation delays, and fluctuations in demand. These risks may develop gradually before becoming visible through conventional operational indicators.

Traditional supply chain risk management generally relies on historical information, periodic audits, manual reporting, safety-stock calculations, and supplier performance evaluations. Such approaches provide an essential foundation for risk control, but their effectiveness may be limited when several independent risk factors interact simultaneously. A supplier may appear financially stable while operating in a region experiencing political instability. Similarly, an organization may maintain adequate inventory levels while remaining dependent on a single source of a critical pharmaceutical ingredient.

This creates a need for more sophisticated risk identification and forecasting mechanisms.

Artificial intelligence offers opportunities to address this requirement by processing large volumes of structured and unstructured information, identifying complex relationships, and detecting patterns that may indicate an emerging disruption. Machine learning algorithms can examine historical procurement records, inventory movements, supplier performance, transportation information, demand patterns, and external risk indicators. Natural language processing can potentially extract relevant information from regulatory announcements, news reports, supplier communications, and geopolitical updates.

The value of these technologies lies not simply in their ability to generate predictions but in their potential to convert fragmented information into actionable managerial intelligence.

For example, an AI-enabled risk intelligence system could identify that a pharmaceutical manufacturer depends heavily on an API supplier located in a region experiencing increasing transportation uncertainty. By combining supplier concentration, delivery performance, inventory coverage, and external geopolitical indicators, the system could estimate the probability and potential consequences of a supply interruption. Managers could then evaluate alternative suppliers, adjust procurement schedules, increase strategically justified inventory, or coordinate with downstream healthcare institutions.

The pharmaceutical sector provides a particularly relevant context for such capabilities because disruptions may have consequences beyond organizational profitability. Medicine shortages can disproportionately affect patients requiring continuous treatment, healthcare facilities operating with limited procurement flexibility, and communities with restricted access to alternative suppliers.

In India, the issue has additional significance. India is a major producer and exporter of generic medicines and plays an important role in international pharmaceutical manufacturing. At the same time, dependence on imported inputs for selected APIs and key starting materials creates vulnerabilities that can affect domestic manufacturing continuity. The challenge is therefore not limited to increasing production capacity; it also involves developing reliable mechanisms for anticipating and managing supply-side uncertainty.

Despite growing interest in digital supply chain transformation, the integration of AI into pharmaceutical risk management remains an evolving area. Many organizations are experimenting with predictive analytics, automation, and digital monitoring, but translating technological capabilities into dependable risk intelligence requires organizational coordination, reliable data, domain-specific knowledge, and appropriate governance.

Against this background, the present study investigates how AI-enabled risk intelligence can contribute to the prediction of pharmaceutical supply chain disruptions. It develops a conceptual framework connecting predictive technologies with organizational resilience, supply chain visibility, and proactive decision-making.

The central argument is that pharmaceutical supply chain resilience should move beyond reactive disruption management towards an anticipatory model in which organizations identify early warning signals, evaluate interconnected vulnerabilities, and initiate mitigation measures before medicine availability is affected.

The study is guided by the following research question:

How can AI-enabled risk intelligence improve the prediction, assessment, and management of disruptions within pharmaceutical supply chains?

II. REVIEW OF LITERATURE

A. Evolution of Supply Chain Risk Management

Supply chain risk management has developed from a predominantly operational discipline into a strategic management function concerned with identifying, evaluating, and controlling uncertainties across interconnected business networks.

Jüttner et al. (2010) emphasized the importance of understanding supply chain vulnerability and the organizational mechanisms required to manage disruption risks. Their work established that supply chain risk cannot be examined exclusively through individual organizational activities because disruptions frequently originate outside the boundaries of a focal firm.

Ho et al. (2015) subsequently examined the broader supply chain risk management literature and identified multiple categories of uncertainty, including supply, demand, operational, environmental, and information-related risks. Their synthesis illustrates that risk management requires a combination of identification, assessment, mitigation, and monitoring rather than dependence on a single control mechanism.

An important development within this literature is the recognition that supply chain disruptions can propagate through interconnected networks. A manufacturing interruption affecting one supplier may create shortages for several downstream organizations. The consequences can become more serious when alternative suppliers are unavailable or when replacement materials require regulatory approval.

This network-based understanding is particularly relevant to pharmaceutical manufacturing, where an interruption in the availability of one critical ingredient may affect several finished pharmaceutical products.

B. Vulnerability and Resilience in Pharmaceutical Supply Chains

Supply chain resilience refers to the ability of an organization or network to anticipate disruptions, respond effectively, adapt operations, and recover from adverse events.

The COVID-19 crisis substantially expanded academic interest in this concept. Queiroz et al. (2022) examined the impact of epidemic outbreaks on supply chains and identified important research directions involving preparedness, digitalization, adaptation, recovery, and sustainability. Their analysis demonstrates that large-scale disruptions require coordinated responses across organizational and institutional boundaries.

PubMed+1

Ivanov (2022) developed the viable supply chain perspective by connecting agility, resilience, and sustainability. This perspective extends conventional resilience thinking because it recognizes that maintaining long-term supply chain operations may require structural changes rather than simply restoring previous operating conditions.

PubMed+1

For pharmaceutical organizations, resilience involves more than maintaining warehouse inventories. It includes:

- Maintaining access to critical APIs and key starting materials.
- Developing alternative manufacturing and procurement arrangements.
- Ensuring reliable cold-chain transportation where required.
- Monitoring quality-related supplier vulnerabilities.
- Maintaining regulatory compliance during sourcing changes.
- Coordinating production and distribution decisions across supply chain participants.

The pharmaceutical supply chain therefore requires resilience mechanisms that consider both commercial continuity and the potential consequences of medicine unavailability.

C. Pharmaceutical Supply Chain Vulnerabilities and Global Dependencies

Pharmaceutical manufacturing depends on a geographically distributed network of suppliers, contract manufacturing organizations, distributors, and logistics providers. Such networks provide economies of scale and access to specialized production capabilities, but they may also create concentrated dependencies.

Vyas et al. (2020) discussed India's dependence on foreign sources for pharmaceutical raw materials and examined how COVID-19 exposed weaknesses in the availability of APIs and related inputs. Their work highlights the relationship between international sourcing dependencies and domestic pharmaceutical manufacturing vulnerability.

MSTM

Joseph and Arun Kumar (2024) further examined India's efforts to strengthen domestic API production through the Production Linked Incentive (PLI) scheme. Their analysis places pharmaceutical supply chain resilience within the broader context of industrial policy, international sourcing strategies, and geopolitical uncertainty.

Sage Journals

These studies suggest that pharmaceutical supply chain vulnerabilities are not merely operational problems. They are also influenced by industrial concentration, international trade relationships, manufacturing capabilities, and government policy.

An AI-enabled approach could complement these structural interventions by identifying supplier concentration risks, monitoring changes in international trade conditions, and estimating the potential consequences of disruptions affecting specific pharmaceutical ingredients.

However, predictive technologies cannot independently eliminate structural dependencies. They can improve awareness and support decisions, but actual resilience also requires alternative production capacity, supplier development, regulatory cooperation, and investment.

D. Artificial Intelligence in Supply Chain Management

Artificial intelligence has become increasingly relevant to supply chain management because of its capacity to process large datasets, recognize patterns, and support decisions under uncertainty.

Its applications extend across demand forecasting, production planning, inventory optimization, transportation management, procurement, supplier evaluation, and anomaly detection.

Dubey et al. (2020) examined the relationship between big data analytics, artificial intelligence, organizational orientation, and operational performance. Their research supports the argument that analytical technologies create organizational value when integrated with managerial capabilities and appropriate decision-making processes.

ScienceDirect

More specifically, Dubey et al. (2021) empirically investigated data analytics capability and organizational flexibility as complementary contributors to supply chain resilience. Using survey responses from 213 Indian manufacturing organizations, the authors found support for the proposed relationships. Their findings are relevant because they connect analytical capacity with the organizational flexibility required to respond to supply chain disruptions.

IDEAS/RePEc

Smyth et al. (2024) conducted a systematic review of AI and prescriptive analytics in supply chain resilience. Their study identified the increasing importance of AI-enabled decision support while emphasizing the fragmented nature of research across technologies and supply chain contexts. This provides a foundation for examining AI as a resilience capability rather than simply an operational automation tool.

DOI+1

A related review by the authors of On the Use of Machine Learning in Supply Chain Management (2025) organized machine learning applications across different supply chain processes, demonstrating the expanding scope of predictive and analytical methods in supply chain research.

Oxford Academic

For pharmaceutical organizations, these technologies may support the identification of risks that cannot be detected efficiently through isolated supplier assessments or traditional reporting systems.

E. Machine Learning and Predictive Risk Assessment

Machine learning is particularly relevant to supply chain disruption prediction because it enables analytical models to identify relationships between historical operational information and subsequent disruptions.

Different algorithms can serve different analytical purposes.

Supervised learning can be used to predict whether a supplier is likely to experience a delivery delay, whether inventory will fall below a critical threshold, or whether a production schedule may be interrupted.

Unsupervised learning can identify unusual procurement patterns, unexpected changes in delivery performance, and abnormal inventory movements without requiring predefined disruption labels.

Time-series forecasting can estimate future demand, lead-time variability, and inventory requirements using historical observations and external explanatory variables.

Natural language processing (NLP) can extract information from regulatory notifications, supplier announcements, geopolitical reporting, and other unstructured information sources.

Graph-based analytics can identify critical suppliers and dependencies across multi-tier supply networks, thereby helping organizations understand how a disruption in one location may affect other manufacturers and healthcare institutions.

These applications are complementary. A demand forecasting model, for example, may predict a sudden increase in medicine consumption, while a supplier-risk model identifies whether the production network has sufficient capacity to respond.

Khaled et al. (2024) discussed the application of machine learning methods to early supply chain disruption identification, distinguishing between supervised learning, deep learning, graph-based approaches, and anomaly detection. Their work also draws attention to the need for improved multi-tier network analysis and standardized early-warning evaluation.

jisem-journal.com

Thomas et al. (2025) provide an additional Indian manufacturing perspective through their examination of machine learning for predicting order delivery delays. Their study illustrates how predictive models can be translated into practical operational decision-support applications.

Inderscience

F. Digital Supply Chain Twins and Risk Intelligence

A digital supply chain twin is a digital representation of a physical supply chain that can be used to monitor operational conditions, simulate alternative scenarios, and examine the potential consequences of disruptions.

Ivanov and Dolgui (2021) discussed the use of digital supply chain twins for managing disruption risks and strengthening resilience in the Industry 4.0 environment.

Such systems can provide a more integrated understanding of supply chain dependencies by connecting production facilities, suppliers, inventory locations, and distribution networks.

In pharmaceutical applications, a digital twin could simulate the consequences of an API manufacturing interruption, a transportation delay, or a sudden increase in demand for essential medicines.

When integrated with AI, the digital twin could move beyond static scenario analysis. It could continuously update its risk estimates using new operational and external information.

This integration is particularly valuable because it connects three distinct management activities:

1. Monitoring actual supply chain conditions.
2. Predicting potential future disruptions.
3. Evaluating alternative responses before implementing them.

However, the effectiveness of digital twins depends on data quality, model calibration, and the accuracy with which real-world supply chain relationships are represented.

G. Critical Evaluation of Existing Literature

The reviewed literature demonstrates substantial progress in supply chain risk management, resilience theory, AI applications, and predictive analytics. Nevertheless, several limitations remain.

First, much of the AI and supply chain literature examines broad manufacturing and logistics contexts. Pharmaceutical supply chains have additional characteristics, including quality assurance requirements, product-specific regulatory approvals, temperature-sensitive distribution, and the clinical consequences of medicine shortages.

Second, many predictive applications focus on individual operational outcomes, such as delivery delays or demand forecasting. These applications may not fully capture the interconnected nature of pharmaceutical disruption risks.

Third, analytical accuracy is not equivalent to organizational preparedness. A model may correctly identify a potential shortage without ensuring that an organization possesses the financial, manufacturing, or regulatory capacity to respond.

Fourth, the literature increasingly recognizes the importance of data analytics capability, but questions remain concerning the integration of external intelligence, multi-tier supplier information, and managerial decision-making.

Finally, pharmaceutical supply chain resilience has an important public policy dimension. Commercial organizations may prioritize profitability, whereas public health authorities must also consider the equitable availability of essential medicines.

Consequently, AI-enabled pharmaceutical risk intelligence should be examined as an integrated organizational and policy capability rather than as an isolated technological application.

III. RESEARCH GAP AND PROBLEM STATEMENT

A. Research Gap

Existing studies provide valuable insights into supply chain vulnerability, pharmaceutical manufacturing dependencies, organizational resilience, and AI-based analytical capabilities. However, an integrated research perspective connecting these dimensions remains necessary.

The following research gaps emerge from the literature.

1. Limited pharmaceutical-specific predictive risk integration

General supply chain prediction models do not always account for pharmaceutical-specific characteristics such as API dependencies, manufacturing quality failures, regulatory requirements, and temperature-controlled distribution.

2. Insufficient integration of internal and external risk signals

Many conventional risk assessment systems emphasize internal operational information. However, pharmaceutical disruptions can originate from external developments, including geopolitical tensions, extreme weather, international trade restrictions, and regulatory interventions.

3. Limited understanding of multi-tier disruption propagation

A pharmaceutical company may have information about its immediate suppliers but limited visibility into the suppliers of those suppliers. This creates uncertainty concerning upstream dependencies and the possible propagation of disruptions.

4. Weak connection between prediction and managerial intervention

Predicting a disruption is not sufficient unless the prediction leads to appropriate action. The relationship between AI-generated warnings, managerial interpretation, and mitigation decisions requires further examination.

5. Limited attention to public health implications

Existing operational approaches frequently emphasize efficiency, cost reduction, and service performance. A pharmaceutical risk intelligence framework should additionally consider medicine criticality, patient consequences, and the potential impact of shortages on healthcare access.

6. Insufficient evidence from emerging pharmaceutical markets

Countries such as India offer an important research context because of their extensive pharmaceutical manufacturing capabilities and exposure to international input dependencies. More sector-specific empirical research is needed to understand how AI-enabled systems can operate under different technological and institutional conditions.

B. Problem Statement

Pharmaceutical supply chains increasingly face complex and interconnected disruptions that can compromise manufacturing continuity and medicine availability. Conventional risk management mechanisms often identify problems after operational performance has already deteriorated, limiting the time available for effective intervention.

Although artificial intelligence provides opportunities for predictive analytics, anomaly detection, and intelligent monitoring, its integration into pharmaceutical supply chain risk management remains insufficiently understood.

The central research problem concerns the absence of a comprehensive pharmaceutical-specific framework that integrates operational information, external risk indicators, multi-tier supplier dependencies, and AI-based predictive capabilities into an actionable decision-support system.

The study therefore proposes an AI-enabled risk intelligence framework designed to improve early disruption identification, risk prioritization, and proactive pharmaceutical supply chain management.

IV. RESEARCH OBJECTIVES AND HYPOTHESES

A. Research Objectives

The primary objective is to examine how AI-enabled risk intelligence can strengthen the prediction and management of pharmaceutical supply chain disruptions.

The specific objectives are:

1. To identify major operational, environmental, technological, and geopolitical risks affecting pharmaceutical supply chain continuity.
2. To examine the potential applications of machine learning and predictive analytics in pharmaceutical disruption forecasting.
3. To develop a conceptual framework integrating internal supply chain data and external risk intelligence.
4. To examine the relationship between AI-enabled risk intelligence and pharmaceutical supply chain resilience.
5. To evaluate the importance of data quality, supply chain visibility, and organizational preparedness in predictive risk management.
6. To propose managerial and policy recommendations for implementing AI-enabled pharmaceutical risk intelligence.

B. Research Hypotheses

Based on the theoretical discussion and identified research gaps, the following hypotheses are proposed for future empirical testing.

Hypothesis	Proposed relationship
H1	AI-enabled risk intelligence has a positive relationship with pharmaceutical supply chain disruption prediction capability.
H2	Supply chain data integration positively influences the effectiveness of AI-based risk intelligence.
H3	Multi-tier supply chain visibility positively influences disruption prediction accuracy.
H4	AI-enabled early-warning capability positively influences pharmaceutical supply chain resilience.
H5	Organizational preparedness positively moderates the relationship between disruption prediction capability and supply chain resilience.
H6	AI-based predictive risk assessment positively influences proactive risk mitigation decisions.

These hypotheses are conceptual propositions. They have not been statistically tested in the present study.

© IARJSET This work is licensed under a Creative Commons Attribution 4.0 International License

V. THEORETICAL AND CONCEPTUAL FRAMEWORK

The proposed framework draws upon four complementary theoretical perspectives: supply chain resilience theory, dynamic capabilities theory, organizational information processing theory, and the viable supply chain perspective.

A. Supply Chain Resilience Theory

Supply chain resilience theory explains how organizations prepare for, absorb, respond to, and recover from disruptive events.

Within the pharmaceutical sector, resilience involves maintaining access to essential raw materials, sustaining manufacturing operations, and ensuring the continued distribution of medicines.

The theory provides the foundation for examining the expected outcome of AI-enabled risk intelligence.

The proposed relationship is that improved identification and assessment of emerging risks can strengthen organizational preparedness and contribute to more effective disruption management.

B. Dynamic Capabilities Theory

Dynamic capabilities theory emphasizes an organization's ability to recognize environmental changes, mobilize resources, and reorganize activities in response to changing conditions.

Applied to pharmaceutical supply chains, AI-enabled risk intelligence may strengthen three interconnected capabilities:

- Sensing: Identifying emerging risks through operational monitoring and external intelligence.
- Seizing: Evaluating available responses and selecting appropriate mitigation measures.
- Transforming: Reconfiguring suppliers, procurement arrangements, inventory strategies, and distribution systems when necessary.

This perspective is important because predictive technologies do not independently generate resilience. Their contribution depends on the organization's ability to convert information into timely action.

C. Organizational Information Processing Theory

Organizational information processing theory explains how organizations respond to uncertainty by developing information-processing mechanisms that match the complexity of their operating environments.

Pharmaceutical supply chains generate information across numerous organizational boundaries. Procurement systems, manufacturing platforms, transportation networks, warehouses, suppliers, and healthcare institutions may each maintain different data structures.

AI-enabled information processing can help combine these information sources and identify relationships that are difficult to recognize through manual reporting.

Dubey et al. (2021) provide empirical support for the importance of data analytics capabilities and organizational flexibility in strengthening supply chain resilience.

D. Viable Supply Chain Perspective

The viable supply chain perspective extends resilience beyond the ability to recover from individual disruptions.

Ivanov (2022) argues that supply chains must retain the ability to adapt their structures and operations under changing environmental conditions.

For pharmaceutical organizations, this implies that predictive risk intelligence should support long-term structural decisions, including:

- Diversification of critical suppliers.
- Development of alternative manufacturing facilities.
- Strategic inventory allocation.
- Regional sourcing arrangements.
- Continuous evaluation of geopolitical and environmental exposure.

 This work is licensed under a Creative Commons Attribution 4.0 International License

E. Proposed Conceptual Model

The four theoretical perspectives collectively inform the proposed conceptual framework.

F. AI-enabled pharmaceutical risk intelligence framework

Input: Integrated risk information

Supplier records • Inventory data • Manufacturing information • Logistics data • Regulatory alerts • Geopolitical intelligence • Demand signals

AI-enabled analytical engine
Machine learning • Anomaly detection • NLP • Time-series forecasting • Network analytics
Predictive risk intelligence

Disruption probability • Risk severity • Early warnings • Supplier vulnerability • Potential network impact

Managerial decision and intervention

Supplier diversification • Inventory adjustment • Alternative sourcing • Production rescheduling • Logistics reconfiguration

Expected outcome
Improved pharmaceutical supply chain resilience

Greater preparedness • Reduced disruption exposure • Improved medicine availability • Stronger operational continuity

Cross-cutting enabling factors: data quality, organizational preparedness, digital infrastructure, governance, human oversight, and regulatory coordination.

The framework illustrates how AI-enabled risk intelligence connects information collection with predictive analysis and operational intervention. Its effectiveness is expected to depend on the quality of available data and the organization's capacity to respond to the identified risks.

VI. RESEARCH METHODOLOGY

A. Research Design

The present study adopts a conceptual and exploratory research design supported by a structured examination and synthesis of existing academic literature.

The research does not involve primary data collection or experimental model validation. Instead, it develops a theoretically grounded framework for understanding how AI-enabled risk intelligence can improve pharmaceutical supply chain disruption prediction.

A conceptual approach is appropriate because the research problem involves integrating multiple research streams, including artificial intelligence, pharmaceutical operations, supply chain resilience, and organizational decision-making.

B. Research Approach

The study follows a qualitative, theory-driven approach. It draws upon published academic studies, research reviews, and documented pharmaceutical supply chain developments from 2010 to 2025.

The literature is examined across five broad themes:

1. Pharmaceutical supply chain vulnerabilities.
2. Supply chain risk management and resilience.
3. Artificial intelligence and machine learning applications.
4. Predictive analytics and digital supply chain systems.
5. Organizational preparedness and pharmaceutical policy.

The selected literature is synthesized to identify relationships between technological capabilities, risk identification, and organizational resilience.

C. Proposed Data Sources for an Empirical Implementation

Although the present paper is conceptual, the proposed framework could be empirically implemented using the following data sources.

Data category	Illustrative variables	Potential source
Procurement	Order frequency, supplier concentration, procurement delays	ERP and procurement systems
Inventory	Stock levels, stock-out frequency, inventory turnover	Warehouse management systems
Manufacturing	Production capacity, downtime, batch rejection	Manufacturing execution systems
Logistics	Delivery time, transit delays, temperature deviations	Logistics and tracking platforms
Supplier risk	Financial instability, geographic concentration, delivery reliability	Supplier databases
External intelligence	Natural disasters, geopolitical events, trade restrictions	Government and international databases
Regulatory information	Manufacturing alerts, quality notices, regulatory changes	National regulatory authorities
Demand	Consumption patterns, seasonal fluctuations, order volumes	Sales and hospital procurement records

The framework would benefit from combining organizational data with publicly available external information. This would make it possible to identify relationships between internal operational vulnerabilities and external disruption indicators.

D. Proposed AI-Based Predictive Model

The proposed system consists of five analytical stages.

Stage 1: Data collection and integration

The first stage involves collecting information from procurement systems, supplier databases, inventory platforms, manufacturing facilities, transportation providers, and external intelligence sources.

Data integration is important because individual operational systems may provide incomplete representations of supply chain risk.

Stage 2: Data preprocessing and feature engineering

Collected information would be cleaned, standardized, and transformed into analytical variables.

Potential features include:

- Supplier delivery reliability.
- Average procurement lead time.
- Lead-time variability.
- Supplier concentration ratio.
- Inventory coverage in days.
- Production downtime frequency.
- Historical quality rejection rates.
- Transportation disruption frequency.
- External geopolitical risk indicators.
- Demand volatility.

Missing values, duplicate records, inconsistent reporting periods, and data quality problems would need to be addressed before model development.

Stage 3: Predictive modelling

Different machine learning algorithms could be evaluated according to the type of risk being predicted.

© IARJSET This work is licensed under a Creative Commons Attribution 4.0 International License

Algorithm	Proposed pharmaceutical application
Random Forest	Supplier failure and delivery delay prediction
XGBoost	Classification of high-risk procurement orders
Long Short-Term Memory (LSTM)	Demand and inventory forecasting
Isolation Forest	Identification of unusual supply chain activities
Natural Language Processing	Extraction of risk information from external reports
Graph Neural Networks	Identification of multi-tier supplier dependencies

A hybrid architecture may be more suitable than relying on a single algorithm because pharmaceutical disruptions can arise from different combinations of operational and external conditions.

Stage 4: Risk scoring and early-warning generation

The predictive model would estimate the probability of disruption and combine this estimate with the potential operational and public health consequences.

A conceptual risk score can be expressed as:
\[R_i=P_i\times I_i \]
Where:

- \(R_i\) = Risk score for a particular supply chain exposure.
- \(P_i\) = Predicted probability of disruption.
- \(I_i\) = Estimated impact of the disruption.

For pharmaceutical applications, impact should incorporate factors such as medicine criticality, availability of substitutes, inventory coverage, and the number of downstream facilities affected.

The risk score could be used to classify potential disruptions into low, moderate, high, and critical categories.

Importantly, this formula is a proposed prioritization mechanism rather than a validated pharmaceutical risk measurement scale.

Stage 5: Decision support and mitigation
The final stage converts predictive alerts into recommended managerial actions.

For example, a high-risk supplier alert could trigger a review of alternative sourcing arrangements, while an inventory shortage prediction could initiate stock reallocation or revised procurement planning.

The final decision should remain subject to human review, regulatory requirements, and pharmaceutical quality considerations.

E. Model Evaluation
The proposed model should be evaluated using historical disruption records and time-based validation.

The following performance indicators are recommended:

Evaluation metric	Purpose
Accuracy	Overall proportion of correct predictions
Precision	Proportion of predicted disruptions that actually occur
Recall	Proportion of actual disruptions successfully identified
F1-score	Balance between precision and recall
ROC-AUC	Ability to distinguish between disruption and non-disruption cases
PR-AUC	Performance when disruption events are relatively rare
Lead time	Time available between an alert and the actual disruption
False alarm rate	Frequency of incorrect disruption alerts
Calibration	Agreement between predicted and observed probabilities

For pharmaceutical applications, recall and warning lead time deserve particular attention. A model with high overall accuracy but poor identification of critical medicine shortages may have limited practical value.

Furthermore, performance should be assessed separately for critical and non-critical medicines. A false negative involving an essential medicine may have considerably greater consequences than an incorrect warning involving a product with multiple available substitutes.

F. Ethical and Governance Considerations

Implementation requires appropriate data governance.

Supplier information may contain commercially sensitive material, while healthcare demand information may involve confidential institutional or patient-related information.

Consequently, organizations should establish data access controls, cybersecurity safeguards, data retention policies, and clear accountability arrangements.

AI-generated recommendations should not automatically override quality assurance procedures, procurement regulations, or human managerial judgment.

VII. DATA ANALYSIS AND INTERPRETATION

A. Analytical Orientation

Since this research is conceptual, no fabricated numerical observations, survey results, regression coefficients, or model accuracy scores are presented.

Instead, this section examines the expected analytical relationships within the proposed framework and explains how the relationships could be evaluated in future empirical research.

B. Identification of Major Pharmaceutical Supply Chain Risk Categories

The proposed framework identifies six major categories of disruption risk.

Risk category	Illustrative warning indicators	Potential consequence
Supplier risk	Delayed deliveries, concentration, financial instability	Raw material shortages
Manufacturing risk	Equipment failure, quality deviations, production downtime	Production interruption
Logistics risk	Transportation delays, route restrictions, temperature excursions	Delayed or compromised deliveries
Demand risk	Sudden consumption increases, forecasting errors	Inventory shortages
Geopolitical risk	Trade restrictions, international conflicts, export controls	Input availability problems
Regulatory risk	Manufacturing restrictions, compliance notices, approval delays	Procurement or production interruption

These categories are interconnected rather than independent.

For example, geopolitical instability may affect transportation routes, which can increase procurement lead times. Increased lead times may subsequently reduce inventory coverage, creating a higher probability of production interruption.

A predictive model capable of examining these relationships could provide a more comprehensive understanding of disruption exposure than conventional risk assessment based on isolated indicators.

C. Expected Relationship Between AI Capability and Disruption Prediction

The first proposed relationship suggests that AI-enabled risk intelligence can improve disruption prediction capability.

Machine learning models may identify recurring relationships between supplier performance, inventory movements, production schedules, and external risk events.

For instance, a gradual deterioration in supplier delivery performance may not immediately trigger a conventional procurement warning. However, an analytical model examining delivery variability alongside regional transportation instability and supplier concentration could identify a developing vulnerability.

The expected benefit is earlier identification of potential disruptions, allowing managers more time to evaluate alternatives.

This relationship requires empirical testing because model performance will depend on the quality, quantity, and representativeness of the available data.

D. Expected Relationship Between Data Integration and Prediction Effectiveness

The second proposed relationship concerns the importance of integrating information from different operational systems.

A procurement database may indicate that a supplier is meeting contractual delivery commitments, while transportation records reveal increasing transit delays. Similarly, inventory records may show adequate aggregate stock while concealing shortages of specific pharmaceutical ingredients.

Integrating these datasets could provide a more accurate assessment of the actual operating environment.

This interpretation is consistent with the findings of Dubey et al. (2021), who identify the complementary importance of data analytics capability and organizational flexibility for supply chain resilience.

E. Expected Relationship Between Supply Chain Visibility and Risk Prediction

Multi-tier visibility is particularly important in pharmaceutical supply chains.

A pharmaceutical manufacturer may directly monitor its API supplier without knowing that the supplier depends on a single upstream producer for a critical intermediate.

This creates hidden exposure.

Graph-based analytical models could represent relationships between suppliers, manufacturing facilities, transportation routes, and downstream distribution networks.

Such models could identify suppliers whose disruption may affect several pharmaceutical products or multiple manufacturing locations.

The expected analytical outcome is an improved understanding of network-level vulnerabilities.

F. Expected Relationship Between Early Warning and Organizational Resilience

Early-warning systems are useful only when organizations possess the capacity to respond.

Consider a hypothetical pharmaceutical manufacturer receiving an AI-generated alert indicating an elevated risk of interruption in the supply of an essential API.

The alert may identify a combination of supplier concentration, increasing procurement lead times, and external trade uncertainty.

The organization could respond by:

1. Reviewing existing API inventory.
2. Contacting alternative qualified suppliers.
3. Evaluating revised procurement schedules.
4. Reviewing production priorities.
5. Coordinating with distribution partners.
6. Monitoring subsequent changes in supplier risk.

The expected benefit is a reduction in the likelihood that the identified risk develops into an unmanaged production or distribution interruption.

However, if alternative suppliers are unavailable or regulatory approval is required before sourcing changes, the organization may still experience a disruption.

This illustrates why organizational preparedness must be considered alongside predictive capability.

G. Proposed Analytical Relationships

The expected relationships can be represented as follows:

Independent variables

- AI-enabled risk intelligence
- Data integration capability
- Multi-tier supply chain visibility

Mediating capability

Disruption prediction and early-warning capability

Dependent variable

Pharmaceutical supply chain resilience

Moderating variable

Organizational preparedness influences how effectively predictive warnings are translated into mitigation and resilience outcomes.

The model suggests that AI-enabled risk intelligence contributes to resilience through improved information processing and early disruption identification. Its practical impact is expected to be stronger when organizations have the resources and flexibility to implement corrective measures.

VIII. DISCUSSION

The proposed framework provides an integrated perspective on the relationship between artificial intelligence, supply chain risk management, and pharmaceutical resilience.

Its central contribution is the recognition that predicting disruptions and managing disruptions should be treated as interconnected managerial activities.

A. From Reactive Risk Management to Predictive Intelligence

Traditional supply chain risk management frequently emphasizes identifying existing problems, documenting supplier performance, and establishing contingency procedures.

These practices remain necessary, but their effectiveness may be restricted when risks develop across several interconnected operational dimensions.

AI-enabled risk intelligence introduces an anticipatory approach. Rather than waiting for a supplier to miss a delivery deadline, organizations can examine early indicators of deteriorating performance and external instability.

This interpretation extends the supply chain resilience perspective by emphasizing the role of predictive information in organizational preparedness.

The findings anticipated by this framework are consistent with Smyth et al. (2024), whose review identifies the potential of AI and prescriptive analytics in strengthening supply chain resilience.

B. The Strategic Importance of External Risk Intelligence

One of the most important contributions of the proposed framework is the integration of external intelligence into pharmaceutical risk assessment.

Internal operational information provides only a partial understanding of supply chain vulnerability.

Geopolitical instability, extreme weather, international trade restrictions, and regulatory developments may create risks before those risks become visible in procurement or inventory reports.

Consequently, pharmaceutical organizations should consider combining internal enterprise information with external intelligence.

This capability may be particularly useful for organizations operating across international manufacturing and distribution networks.

Nevertheless, external information requires careful interpretation. News reports, political developments, and unverified supplier announcements should not automatically be treated as confirmed disruption events.

The system must distinguish between verified incidents, emerging warnings, and uncertain information.

C. AI and the Problem of Multi-Tier Dependencies

Pharmaceutical supply chains frequently contain multiple levels of suppliers, manufacturers, intermediaries, and logistics providers.

The inability to observe upstream relationships creates uncertainty concerning the potential consequences of disruption.

Graph-based analytics could improve the identification of highly connected suppliers and critical nodes within these networks.

For example, a single upstream API producer may indirectly support several pharmaceutical manufacturers. Its interruption could therefore generate a network-wide shortage rather than an isolated procurement problem.

This approach is consistent with the broader supply chain viability perspective advanced by Ivanov and Dolgui (2020), which emphasizes the importance of interconnected supply networks and disruption propagation.

D. Organizational Preparedness as a Condition for Success

An important distinction must be made between predicting a disruption and preventing its consequences.

A highly accurate prediction system may have limited organizational value when managers cannot access alternative suppliers, increase manufacturing capacity, or adjust procurement arrangements.

This means AI adoption should be accompanied by investments in organizational flexibility.

Pharmaceutical companies should establish clear procedures for reviewing risk alerts, assigning responsibilities, evaluating alternative sourcing options, and coordinating with suppliers and distributors.

The dynamic capabilities perspective is useful here because it explains how information becomes strategically valuable when organizations possess the ability to act upon it.

E. Implications for Pharmaceutical Policy

The discussion also has important implications for public policy.

Medicine availability is a public health concern, and supply chain disruptions can affect healthcare institutions and patients beyond the organizations directly involved.

Governments may therefore benefit from developing coordinated pharmaceutical risk monitoring systems that connect manufacturers, distributors, healthcare institutions, and regulatory authorities.

In India, such initiatives could complement existing efforts to strengthen domestic API manufacturing and reduce excessive dependence on concentrated international supply sources.

The Production Linked Incentive policy provides an industrial policy response to selected manufacturing dependencies. AI-enabled risk intelligence could complement such initiatives by improving the identification of emerging supply vulnerabilities.

However, government intervention should balance the benefits of information sharing with commercial confidentiality, cybersecurity, and fair competition.

F. Limitations and Critical Concerns

AI-enabled risk intelligence also introduces important challenges.

Data fragmentation: Different supply chain participants may use incompatible information systems, limiting the ability to create a unified risk assessment.

Algorithmic bias: Historical datasets may underrepresent unusual or unprecedented events, resulting in unreliable predictions during extraordinary disruptions.

False alerts: Excessive incorrect warnings may lead to unnecessary inventory accumulation, increased procurement costs, and reduced managerial confidence.

Cybersecurity: Greater digital integration increases exposure to unauthorized access, data manipulation, and cyberattacks.

Algorithmic opacity: Managers may find it difficult to understand why a system has classified a particular supplier or product as high risk.

Unequal technological capacity: Smaller manufacturers and distributors may lack the financial and technical resources required to implement sophisticated predictive systems.

Regulatory constraints: Alternative suppliers cannot always be engaged immediately because pharmaceutical sourcing and manufacturing changes may require quality assessments and regulatory approvals.

These limitations suggest that AI should complement, rather than replace, human judgment and established pharmaceutical quality management practices.

IX. FINDINGS, IMPLICATIONS, AND RECOMMENDATIONS

A. Major Findings

The conceptual analysis produces the following key findings.

Finding 1: Pharmaceutical supply chain disruptions require integrated risk assessment.

Disruptions are frequently associated with multiple interacting factors rather than a single operational failure. Supplier concentration, transportation uncertainty, demand fluctuations, and geopolitical developments may collectively increase vulnerability.

Finding 2: AI offers opportunities for earlier disruption identification.

Machine learning, predictive analytics, and natural language processing can potentially identify warning signals that are difficult to detect through conventional monitoring mechanisms.

Finding 3: Data integration is essential for reliable risk intelligence.

The usefulness of predictive models depends on their ability to access consistent information across procurement, manufacturing, inventory, logistics, and external intelligence systems.

Finding 4: Multi-tier supply chain visibility is strategically important.

Monitoring immediate suppliers alone may not reveal vulnerabilities originating among upstream manufacturers and raw material providers. Network-based analytical approaches could improve visibility into these dependencies.

Finding 5: Predictive capability does not automatically create resilience.

Organizations must possess sufficient operational flexibility, alternative sourcing arrangements, managerial coordination, and financial resources to act on AI-generated warnings.

Finding 6: Pharmaceutical risk intelligence has wider public health implications.

Predicting disruptions involving essential medicines may help organizations and policymakers prioritize resources according to medicine criticality and potential patient consequences.

B. Managerial Implications

The proposed framework offers several implications for pharmaceutical industry managers.

First, pharmaceutical companies should incorporate predictive risk intelligence into strategic procurement planning rather than restricting AI applications to demand forecasting and inventory optimization.

Second, procurement departments should develop supplier risk profiles that incorporate financial, geographical, operational, and performance-related information.

Third, supply chain managers should establish cross-functional coordination between procurement, production, quality assurance, logistics, information technology, and regulatory affairs.

Fourth, pharmaceutical organizations should establish clearly defined procedures for responding to AI-generated alerts.

Finally, managers should evaluate AI investments according to their contribution to supply continuity, operational preparedness, and medicine availability rather than measuring success exclusively through cost savings.

C. Implications for Pharmaceutical Manufacturers

Manufacturers should prioritize the following initiatives:

- Develop predictive supplier monitoring systems.
- Identify critical APIs and key starting materials with concentrated sourcing dependencies.
- Integrate procurement and manufacturing information.
- Establish early-warning mechanisms for production interruptions.
- Develop alternative qualified supplier arrangements.
- Conduct periodic supply chain stress testing.
- Incorporate AI-generated risk assessments into business continuity planning.

Manufacturers should also distinguish between routine procurement risks and risks involving medicines with limited therapeutic substitutes.

D. Implications for Distributors and Logistics Providers

Distributors and logistics providers play a critical role in maintaining the movement of medicines from manufacturing facilities to healthcare institutions.

They should consider using predictive models to monitor transportation delays, warehouse capacity, cold-chain deviations, and regional distribution vulnerabilities.

Integration with manufacturer and healthcare institution information systems could also improve the identification of regional shortages.

E. Policy Recommendations

The following policy recommendations are proposed, particularly for pharmaceutical manufacturing economies such as India.

Policy area	Recommended intervention	Expected benefit
Digital infrastructure	Develop interoperable pharmaceutical supply chain information systems	Improved information visibility
API security	Monitor concentration in critical API sourcing	Reduced dependency exposure
Early-warning systems	Establish coordinated disruption monitoring	Faster institutional response
Data governance	Introduce common standards for responsible data sharing	Greater trust and security
SME support	Provide digital capability development programmes	Wider technology adoption
Regulatory coordination	Improve information exchange between regulators and manufacturers	Better disruption preparedness
Public health	Prioritize critical and essential medicines in risk monitoring	Improved medicine availability

F. Specific Recommendations for India

India's pharmaceutical industry has an important opportunity to integrate AI-based risk intelligence with broader pharmaceutical manufacturing and industrial development initiatives.

The following measures deserve consideration:

1. National pharmaceutical risk intelligence infrastructure: Develop a coordinated mechanism for monitoring critical pharmaceutical inputs, manufacturing dependencies, and emerging supply risks.

2. API dependency mapping: Encourage manufacturers to document and monitor upstream dependencies involving APIs, key starting materials, and drug intermediates.

3. AI adoption support: Provide technical assistance and digital infrastructure support to small and medium-sized pharmaceutical manufacturers.

4. Public-private collaboration: Encourage information sharing between manufacturers, logistics providers, healthcare institutions, and relevant government agencies.

5. Medicine criticality assessment: Develop risk prioritization approaches that consider therapeutic importance, availability of alternatives, and potential consequences of shortages.

6. Predictive stress testing: Encourage periodic simulations examining the effects of supplier failure, transportation disruption, and sudden demand increases.

These recommendations should complement domestic manufacturing development rather than substitute for it. Predictive intelligence can reveal vulnerabilities, but long-term resilience also requires adequate production capacity and diversified sourcing.

X. CONCLUSION AND SCOPE FOR FUTURE RESEARCH

A. Conclusion

Pharmaceutical supply chain disruptions represent an important challenge for manufacturers, healthcare institutions, distributors, and policymakers. The increasing complexity of global pharmaceutical production networks has created interconnected dependencies that make traditional risk management approaches less effective when dealing with rapidly evolving and multi-dimensional uncertainties.

This study examined the potential of AI-enabled risk intelligence to strengthen the prediction and management of pharmaceutical supply chain disruptions. Drawing upon supply chain resilience theory, dynamic capabilities theory, organizational information processing theory, and the viable supply chain perspective, it developed a conceptual framework connecting information integration, predictive analytics, early-warning mechanisms, managerial intervention, and supply chain resilience.

The analysis indicates that artificial intelligence can potentially improve pharmaceutical risk identification through machine learning, time-series forecasting, anomaly detection, natural language processing, and network analytics. These capabilities may help organizations identify emerging supplier vulnerabilities, estimate procurement disruptions, anticipate inventory shortages, and evaluate the potential consequences of external developments.

However, the study also establishes an important distinction between predictive accuracy and actual organizational resilience. The ability to anticipate a disruption does not guarantee the ability to prevent its consequences. Effective risk management additionally requires organizational flexibility, alternative sourcing arrangements, regulatory coordination, reliable information systems, and appropriate managerial intervention.

For pharmaceutical companies, the strategic value of AI therefore lies in its ability to transform fragmented operational information into actionable risk intelligence. For policymakers, it offers opportunities to strengthen pharmaceutical preparedness, improve visibility into critical supply dependencies, and support the continuity of essential medicine availability.

In the Indian pharmaceutical context, predictive risk intelligence could complement domestic API manufacturing initiatives, supplier diversification, and broader industrial resilience strategies.

© IARJSET This work is licensed under a Creative Commons Attribution 4.0 International License

The central conclusion is that the future of pharmaceutical supply chain management should not depend exclusively on reacting to disruptions after they occur. Instead, organizations should develop integrated capabilities to anticipate emerging vulnerabilities, evaluate potential consequences, and initiate preventive measures.

AI-enabled risk intelligence represents a promising approach to achieving this transition, provided that its implementation is supported by reliable data, responsible governance, and human-centred decision-making.

B. Scope for Future Research

The present study develops a conceptual framework and identifies several opportunities for further investigation.

1. Empirical validation of the proposed framework

Future studies could collect primary data from pharmaceutical manufacturers, procurement professionals, supply chain managers, and logistics providers to statistically examine the proposed hypotheses.

2. Development of pharmaceutical-specific machine learning models

Researchers could develop and compare Random Forest, XGBoost, LSTM, and graph-based models using pharmaceutical procurement, supplier, inventory, and disruption datasets.

3. Comparative research across geographical markets

Comparative studies involving India, China, Europe, and the United States could investigate how differences in pharmaceutical manufacturing structures and regulatory environments influence AI adoption.

4. Research on essential medicine shortages

Future research could examine whether AI-enabled early-warning systems can improve the identification of shortages involving essential medicines and products with limited therapeutic substitutes.

5. Integration of digital twins and predictive analytics

Researchers could examine how digital supply chain twins can simulate pharmaceutical disruption scenarios and support alternative procurement and production decisions.

6. AI governance and accountability

Further research should investigate algorithmic transparency, cybersecurity, data ownership, supplier confidentiality, and the responsibility of managers when AI-generated predictions prove inaccurate.

7. Economic evaluation of predictive risk intelligence

Future empirical studies could assess whether AI implementation generates measurable improvements in procurement efficiency, inventory costs, disruption lead time, and medicine availability.

Ultimately, the proposed framework should be tested using longitudinal pharmaceutical supply chain data. Such research would help establish whether AI-enabled risk intelligence produces measurable improvements in disruption prediction and organizational resilience.

REFERENCES

[1]. APA 7th edition
[2]. The following references are drawn from identifiable academic publications published between 2010 and 2025. Their bibliographic details and DOI links should be checked against the final journal submission requirements.
[3]. Christopher, M., & Peck, H. (2004). Building the resilient supply chain. The International Journal of Logistics Management, 15(2), 1–14. https://doi.org/10.1108/09574090410700275
[4]. Dubey, R., Gunasekaran, A., Childe, S. J., Bryde, D. J., Giannakis, M., Foropon, C., Roubaud, D., & Hazen, B. T. (2020). Big data analytics and artificial intelligence pathway to operational performance under the effects of

entrepreneurial orientation and environmental dynamism: A study of manufacturing organisations. International Journal of Production Economics, 226, Article 107599. https://doi.org/10.1016/j.ijpe.2019.107599

[5]. Dubey, R., Gunasekaran, A., Childe, S. J., Fosso Wamba, S., Roubaud, D., & Foropon, C. (2021). Empirical investigation of data analytics capability and organizational flexibility as complements to supply chain resilience. International Journal of Production Research, 59(1), 110–128. https://doi.org/10.1080/00207543.2019.1582820

[6]. Ho, W., Zheng, T., Yildiz, H., & Talluri, S. (2015). Supply chain risk management: A literature review. International Journal of Production Research, 53(16), 5031–5069. https://doi.org/10.1080/00207543.2015.1030467

[7]. Ivanov, D. (2022). Viable supply chain model: Integrating agility, resilience and sustainability perspectives—Lessons from and thinking beyond the COVID-19 pandemic. Annals of Operations Research, 319, 1411–1431. https://doi.org/10.1007/s10479-020-03640-6

[8]. Ivanov, D., & Dolgui, A. (2020). Viability of intertwined supply networks: Extending the supply chain resilience angles towards survivability. A position paper motivated by COVID-19 outbreak. International Journal of Production Research, 58(10), 2904–2915. https://doi.org/10.1080/00207543.2020.1750727

[9]. Ivanov, D., & Dolgui, A. (2021). A digital supply chain twin for managing the disruption risks and resilience in the era of Industry 4.0. Production Planning & Control, 32(9), 775–788. https://doi.org/10.1080/09537287.2020.1768450

[10]. Joseph, R. K., & Arun Kumar, R. (2024). Making global pharma supply chain resilient: Will the PLI scheme of India make it a reliable alternative to China for the supply of APIs? Indian Economic & Social History Review, 74(1). https://doi.org/10.1177/00194662241265475

[11]. Jüttner, U., Peck, H., & Christopher, M. (2010). Supply chain risk management: Outlining an agenda for future research. International Journal of Logistics Research and Applications, 6(4), 197–210. https://doi.org/10.1080/13675560310001627016

[12]. Khaled, M. A., Nadeem, M., Mansour, A. G. E. A., Kulfod, A. A. M., & Aziz, M. A. (2024). Machine learning approaches for early prediction of supply-chain disruptions and operational risks. Journal of Information Systems Engineering and Management, 9(4s). https://doi.org/10.52783/jisem.v9i4s.14812

[13]. Queiroz, M. M., Ivanov, D., Dolgui, A., & Fosso Wamba, S. (2022). Impacts of epidemic outbreaks on supply chains: Mapping a research agenda amid the COVID-19 pandemic through a structured literature review. Annals of Operations Research, 319, 1159–1196. https://doi.org/10.1007/s10479-020-03685-7

[14]. Ray, A. (2020). Managing supply chain aspects of the COVID-19 pandemic in India. Indian Chemical Engineer, 62(4), 396–401. https://doi.org/10.1080/00194506.2020.1845989

[15]. Smyth, C., Dennehy, D., Fosso Wamba, S., Scott, M., & Harfouche, A. (2024). Artificial intelligence and prescriptive analytics for supply chain resilience: A systematic literature review and research agenda. International Journal of Production Research, 62(23), 8537–8561. https://doi.org/10.1080/00207543.2024.2341415

[16]. Thomas, A., Panicker, V. V., & Midhun, R. P. (2025). Application of machine learning algorithms in supply chain disruption management: An Indian MSME perspective. International Journal of Industrial and Systems Engineering, 48(4), 487–510. https://doi.org/10.1504/IJISE.2024.143708

[17]. Vyas, N., Joshi, A., Malviya, S., & Kharia, A. (2020). Reduced pharma supply chain in COVID-19: Measures to reduce India's reliance for active pharmaceutical ingredients on China and other countries. Indian Journal of Pharmaceutical Education and Research, 54(4), 835–842. https://doi.org/10.5530/ijper.54.4.175

[18]. Roy, A., Mohapatra, A., Sharwan, C., Kumar, A., Kumar, S., Maholay, A., & Conneh, C. C. (2025). Artificial intelligence in pharmaceutical supply chain management: A systemic review. World Journal of Biology Pharmacy and Health Sciences, 21(1), 204–213. https://doi.org/10.30574/wjbphs.2025.21.1.1088

© IARJSET This work is licensed under a Creative Commons Attribution 4.0 International License